计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| D414239-5mg |
5mg |
现货 ![]() |
| |
| D414239-10mg |
10mg |
现货 ![]() |
| |
| D414239-25mg |
25mg |
现货 ![]() |
| |
| D414239-50mg |
50mg |
现货 ![]() |
| |
| D414239-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | Deucravacitinib | NSC825520 | compound 11 [PMID: 31318208} | EN300-22276121 | Deucravacitinib [USAN] | (BMS-986165) | SCHEMBL20520348 | Sotyktu | AT18623 | DEUCRAVACITINIB [JAN] | 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3 |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Deucravacitinib (BMS-986165) |
| 生化机理 | Deucravacitinib(BMS-986165)是一种高效、高选择性的 Tyk2 异构体抑制剂,与 Tyk2 伪激酶结构域结合的 Ki 值为 0.02 nM。它对265种激酶和伪激酶具有高度选择性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 酪氨酸蛋白激酶 TYK2 负异位调节剂 |
| 产品介绍 |
BMS-986165 是一种高选择性、口服生物可利用的变构 TYK2 抑制剂,用于治疗自身免疫性疾病。它通过稳定调节 JH2 结构域来阻断受体介导的 Tyk2 激活,可抑制IL-12/23和 I 型IFN 途径。 Information Deucravacitinib (BMS-986165) Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases. Targets Tyk2 (Cell-free assay) 0.02 nM In vitro BMS-986165 is highly differentiated from all other reported JAK/TYK2 inhibitors due to its ability to achieve an unprecedented level of selectivity for TYK2, especially over JAK1, JAK2, and JAK3. In vivo BMS-986165 has been identified as a highly potent and selective allosteric TYK2 inhibitor having excellent PK properties across species with minimal profiling liabilities and is orally efficacious with dose-dependent activity in a murine disease model of psoriasis. Significant activity has also been observed with 11 in other murine autoimmune disease models of colitis and lupus. Cell Research(from reference) Cell lines:CD3+ T-cells, CD161+ CD3+ T-cells, TF-1 cells, mononuclear cells, platelets Concentrations:0 - 10 μM |
| 纯度 | ≥98% |
| ALogP | 1.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide |
| INCHI | 1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3 |
| InChi Key | BZZKEPGENYLQSC-FIBGUPNXSA-N |
| Smiles | CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 |
| Isomeric SMILES | [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 |
| 分子量 | 425.46 |
| Reaxy-Rn | 41849078 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=41849078&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 29 mg/mL (68.16 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| 分子量 | 425.500 g/mol |
| XLogP3 | 1.200 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 425.2 Da |
| 单同位素质量Monoisotopic Mass | 425.2 Da |
| 拓扑极表面积Topological Polar Surface Area | 136.000 Ų |
| 重原子数Heavy Atom Count | 31 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 648.000 |
| 同位素原子数Isotope Atom Count | 3 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
¥999.90
¥1,102.90
¥3,999.90
¥528.90
¥621.90
| 1. Schlapbach C, Conrad C. (2022) TYK-ing all the boxes in psoriasis.. J Allergy Clin Immunol, 149 (6): (1936-1939). [PMID:35341877] |
| 2. Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S. (2018) Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.. N Engl J Med, 379 (14): (1313-1321). [PMID:30205746] |
| 3. Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L et al.. (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.. J Med Chem, 62 (20): (8973-8995). [PMID:31318208] |
| 4. Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD et al.. (2019) Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.. Sci Transl Med, 11 (502): [PMID:31341059] [10.1126/scitranslmed.aaw1736] |
| 5. Chang Y, Xu S, Ding K. (2019) Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.. J Med Chem, 62 (20): (8951-8952). [PMID:31603320] |